News

Public · Published

Spyre Therapeutics Price Target Cut to $120.00/Share From $123.00 by Wedbush

Wedbush cut its price target for Spyre Therapeutics to $120.00 per share from $123.00 per share. The supplied article also says Wedbush maintained its Outperform rating on the company.

Published:

Updated:

What happened

Wedbush cut its price target for Spyre Therapeutics to $120.00 per share from $123.00 per share. The supplied article also says Wedbush maintained its Outperform rating on the company.

Confirmed

Global impact / market context

A price target is an analyst’s estimate of a share’s possible value, not a guaranteed outcome. The lower estimate signals a less favorable valuation view from Wedbush, while keeping Outperform indicates it still rates the shares positively; neither action directly changes Spyre’s sales or cash.

Analyst inference

The article provides no reason for the target cut, financial results, or share-price response. Investors therefore cannot tell from this item whether Wedbush changed its assumptions about Spyre’s research costs, future revenue, or funding needs, so the rating action alone offers limited evidence about business performance.

Analyst inference

What to watch

  1. Look for a later Wedbush explanation of why it lowered Spyre’s target from $123.00 to $120.00 per share; the supplied report gives no reason for the change. Analyst inference
  2. Check whether Wedbush makes another rating or target change for Spyre; the supplied report says it maintained Outperform while lowering its target to $120.00 per share. Analyst inference
  3. Compare future Spyre analyst-rating reports with this update, which reports both a lower Wedbush target and an unchanged Outperform rating; no other analyst views are provided here. Analyst inference

Evidence

  • Original source link unavailable